The testing cohort of 103 patients were all advanced EGFR-mutant lung adenocarcinoma patients, including 95 (92.2%) with acquired resistance to EGFR-TKIs and 8 (7.8%) with de novo T790M. Here, EGFR is linked to lung adenocarcinoma.